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ABSTRACT
Background: Postoperative nausea and vomiting (PONV) are potential com-
plications in patients after laparoscopic cholecystectomy (LC). Combination anti-
emetic therapy often is effective for preventing PONV in patients undergoing LC,
and combinations of antiemetics targeting different sites of activity may be more
effective than monotherapy.
Objective: The aim of this study was to compare the administration of a
ubhypnotic dose of propofol combined with dexamethasone with one of propofol
ombined with metoclopramide to prevent PONV after LC.
Methods: Sixty adult patients scheduled for LC were randomly assigned to 1 of
2 treatment groups. The patients in group 1 received 0.5 mg/kg propofol plus 8 mg
dexamethasone, and those in group 2 received 0.5 mg/kg propofol plus 0.2 mg/kg
metoclopramide. The number of patients experiencing nausea and vomiting at 0 to
4, 4 to 12, and 12 to 24 hours postoperatively and as well as additional use of rescue
antiemetics were recorded.
Results: The total PONV rates up to 24 hours postanesthesia were 23.3% and
50% for group 1 and group 2, respectively. Comparisons of the data revealed that at
0 to 4 hours, the number of patients experiencing vomiting was 6 (20%) in group 1
and14 (46.7%) in group 2 (P  0.028). The frequency of vomiting in group 1 was
significantly lower than that for group 2 (P  0.028), and the rate of rescue
antiemetic use in group 2 was higher than that in group 1 (20% vs 46.7%; P 
0.028). In the evaluation of PONV based on the nausea and vomiting scale scores, the
mean PONV score was 0.4 (0.2) in group 1 compared with 1.0 (0.2) in group 2
(P 0.017). There were no significant differences between the values at 4 to 12 hours
and at 12 to 24 hours. The frequency of adverse reactions (respiratory depression:
1.3%, 1.3%; laryngospasm: 1.3%, 0%; cough: 1.3%, 0%; hiccup: 1.3%, 0%;) was
not significantly different in the 2 groups.
Accepted for publication February 14, 2011. doi:10.1016/j.curtheres.2011.02.002
2011 Elsevier HS Journals, Inc. All rights reserved. 0011-393X/$ - see front matter
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Current Therapeutic ResearchConclusions: Administration of a subhypnotic dose of 0.5 mg/kg propofol
plus 8 mg dexamethasone at the end of surgery was more effective than administra-
tion of 0.5 mg/kg propofol plus metoclopramide in preventing PONV in the early
postoperative period in adult patients undergoing LC. (Curr Ther Res Clin Exp. 2011;
72:1-12) © 2011 Elsevier HS Journals, Inc. All rights reserved.
Key words: dexamethasone, laparoscopic cholecystectomy, metoclopramide,
postoperative nausea and vomiting, propofol.
INTRODUCTION
Postoperative nausea and vomiting (PONV) are the most common symptoms affect-
ing patients after surgery under general anesthesia, with an incidence of approxi-
mately 30%.1
The true incidence of PONV is difficult to determine because of the lack of a single
timulus of onset as well as the range of possible etiologies (medical, surgical, and patient
nd anesthesia associated). In the absence of antiemetic treatment, the incidence of PONV
s estimated to be 25% to 30% for all surgical interventions and patient populations.2
However, the incidence rate of PONV after laparoscopic cholecystectomy (LC) is higher
than that after other types of surgery.3,4 A rate of 46% to 75% has been reported for
atients who did not receive antiemetic treatment after LC.3–5
Propofol was first reported to be an effective antiemetic at low doses in patients
ndergoing chemotherapy for cancer.6 Song et al7 have shown that intravenous (IV)
administration of 0.5 mg/kg propofol, a low dose, at the end of surgery was effective
in preventing nausea and vomiting after LC.
The use of propofol to maintain anesthesia also reduces PONV. Patients admin-
istered propofol to induce anesthesia have a lower incidence of PONV after LC than
do those administered thiopentone/halothane for anesthesia. Further, it has been
shown that propofol possesses direct antiemetic properties that are not attributable to
the lipid in the emulsion formulation of the drug, as once hypothesized.8
Dexamethasone may offer additional benefits over traditional antiemetics in im-
roving surgical outcomes. Several studies have shown that dexamethasone, a corti-
osteroid, is an effective antiemetic for PONV prophylaxis,9–11 and Holte and
ehlet9 reported that dexamethasone produces antiemetic effects in various types of
urgery. Compared with placebo, dexamethasone, 8 mg IV given 90 minutes before
C, has been reported to reduce PONV significantly.12 Dexamethasone is inexpensive
and effective, with minimal adverse effects after single-dose administration.13
Metoclopramide is a central D2-receptor antagonist and a prokinetic agent that
hastens esophageal clearance, accelerates gastric emptying, and shortens bowel transit
time.14 As an antiemetic, metoclopramide is widely used in clinical practice.2,15
Prophylactic IV administration of metoclopramide, 10 to 20 mg, reduces the inci-
dence of PONV after LC and is as effective as ondansetron, 4 to 8 mg.16,17 At higher
doses (0.2 mg/kg), metoclopramide is associated with extrapyramidal reactions such
as akathisia and motor restlessness.2,15 None of the antiemetics currently available is
ntirely effective, perhaps because most of them act through the blockade of 1
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M. Arslan et al.receptor. Combination antiemetic therapy often is effective for preventing PONV in
patients undergoing LC,8,18,19 and agents with different sites of activity may be more
ffective than a single drug.8
Although reports on propofol and steroid combination therapy are available, no
vidence was uncovered regarding the effects of a combination of propofol plus
etoclopramide and propofol plus dexamethasone for the prevention of PONV. A
EDLINE literature search (inception–2009) using the terms PONV, antiemetic,
ropofol, metoclopramide, and dexamethasone did not identify any studies regarding the
ffects of a combination of propofol plus metoclopramide and propofol plus dexa-
ethasone for the prevention of PONV.
This prospective, randomized, double-blind study aimed to evaluate the effective-
ess and tolerability of a low dose of propofol plus 8 mg dexamethasone and a low
ose of propofol plus metoclopramide for the prevention of PONV in patients
ndergoing LC.
METHODS
This randomized, double-blind, controlled clinical study was carried out at the
Yüksek I˙htisas Hospital in Kırıkkale,Turkey. Approval was obtained from the Ethics
Committee at Kirikkale University Medical School, Kirikkale, Turkey. All patients
provided written informed consent. Sixty patients scheduled for LC (aged 25 to 55
years; 48 women) with an American Society of Anesthesiologists (ASA) physical
status classification system risk of 1 or 2 were randomly assigned to 1 of 2 groups: the
propofol plus 8 mg dexamethasone group (group 1) and the propofol plus 0.2 mg/kg
metoclopramide group (group 2). Patients were assigned using a computer-generated
random number table. Indications for LC in this clinical trial were symptomatic
cholelithiasis, chronic cholecystitis, and cholecystic polyp. Exclusion criteria included
history of hepatic, renal, or cardiovascular diseases; chronic obstructive pulmonary
disease; hematologic or gastrointestinal disorders, or both; hypersensitivity to propo-
fol or to any other drug; history of vertigo or motion sickness; previous postoperative
emesis; pregnant, breastfeeding, or menstruating women; use of an antiemetic agent
within 24 hours before surgery; and laparoscopy replaced by laparotomy. All LC
procedures were performed by the same team of anesthesiologists and surgeons.
Different anesthesiologists carried out the data collection and treating roles in this
study.
Patients fasted for 8 hours before surgery, and no one was premedicated. In the
operation room, heart beat rate (HBR), systolic arterial pressure (SAP), diastolic
arterial pressure (DAP), mean arterial pressure (MAP), and peripheric oxygen satu-
rations (SpO2; Datascope Passport 2, Datascope Corp, Mahwah, New Jersey) were
onitored. Anesthesia for all patients in both groups was induced with thiopentone
mg/kg (IV bolus dose) followed by remifentanil infusion at 0.2 g/kg/min and
evoflurane inspiration at 1% to 2 % concentration. After patients received vecuro-
ium (0.1 mg/kg), all were ventilated mechanically with O2/air (50%/50%), 4 L/min
nd tidal carbon dioxide (ETCO2) 35 to 40 mm Hg through orotracheal intubation
TMS Maxi 2200 M, Penlon AV 900, Oxford, United Kingdom). The maintenance
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Current Therapeutic Researchdoses of remifentanil and sevoflurane were adjusted for hemodynamic stability.
Throughout surgery, hydration was maintained with an infusion of isotonic or
Ringer’s lactate solution at a rate of 3 mL/kg to 5 mL/kg. Hemodynamic parameters
and SpO2 measures were recorded before and after the infusion, every 5 minutes for
0 minutes after intubation, in 15-minute intervals thereafter, and every 30 minutes
or the remainder of the 24-hour postoperative period.
Before induction of anesthesia and at the time of skin closure, patients in group
were given 0.5 mg/kg of propofol (IV bolus dose; propofol 1%) plus 8 mg
examethasone Deksamet® amp, Osel, Istanbul, Turkey (8 mg/2 mL). Group 2
patients were given 0.5 mg/kg propofol (IV bolus; propofol 1% Primperan® amp,
Biofarma, Istanbul, Turkey) plus 0.2 mg/kg metoclopramide IV (10 mg/2mL)
before skin incision closure. All syringes—propofol plus dexamethasone and
propofol plus metoclopramide—were prepared by the same investigator. Patients
in each group received 2 syringes, 1 active and 1 placebo. Patients, the anesthe-
siologist attending during surgery, and the anesthesiologist who collected post-
operative data were all blinded to the randomization process and the identity of
the study drugs.
At the time of the last surgical suture, all anesthetic maintenance agents were
terminated and the time was recorded. The lungs were manually ventilated with
100% oxygen (4 L/min) until spontaneous respiration was achieved. Residual muscle
relaxation was antagonized with 0.03 mg/kg neostigmine and 0.02 mg/kg atropine,
and the patients were appropriately extubated. Time of extubation; eye opening;
response to verbal stimulation; and orientation to place, time, and people were
recorded.
All patients were removed to postoperative recovery and remonitored after extu-
bation. Patients remained for evaluation of potential postoperative complications and
recovery for at least 1 hour.
The primary end point of this study was the total PONV rate up to 24 hours
postanesthesia. The secondary end points were incidence of nausea, incidence of
vomiting, severity of nausea, use of rescue antiemetic drugs, and occurrence of side
effects for 24 hours postanesthesia. All episodes of PONV (nausea or vomiting),
whether in the care unit or in the general ward, were recorded during the first 24
hours after anesthesia in 3 time periods (0 to 4, 4 to 12, and 12 to 24 hours
postanesthesia).
The degree of PONV was scored using the nausea-vomiting scale (NVS) (Table I)
at 0 to 4, 4 to 12, and 12 to 24 hours. Additional antiemetics (10 mg metoclopro-
pamide) were administered intravenously when the NVS score was 3. Patients were
observed for 24 hours postoperatively, and nausea and vomiting times and times of
additional antiemetic and analgesic administration were recorded.
Statistical analyses were performed by SPSS statistical package for Windows
(Chicago, Illinois). Parametric values were evaluated with the Student t-test. Non-
parametric values were compared using the Mann-Whitney U test. Side effects,
gender, and ASA status were compared using 2 and Fisher exact tests. A P  0.05
was considered statistically significant.
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A total of 64 patients were approached for study inclusion, 4 of whom were excluded
based on criteria described previously. Sixty patients (mean [SD] age, 42.15 [8.85]
years; height, 165.85 [7.6] cm; and weight, 71.65 [9.1] kg) completed the study
(Table II). No statistically significant between-group differences were found in the
patients’ demographic and clinical characteristics.
The total PONV rates up to 24 hours postanesthesia were 23.3% and 50% in
groups 1 and 2, respectively.The comparisons of the groups for the number of patients
with nausea showed a significant difference at 0 to 4 hours, whereas there were no
statistically significant differences at 4 to 12 and at 12 to 24 hours. The incidence of
nausea at 0 to 4 hours was 7 patients (23.3%) in group 1, 15 (50%) in group 2
(P  0.032). The incidence rate of vomiting in group 1 was statistically significantly
lower than that in group 2 (20% vs 46.7%; P  0.028). The comparisons of the
roups for the incidence of vomiting at 0 to 4 hours revealed a rate of 6 patients (20%)
n group 1 and 14 patients (46.7 %) in group 2 (Table III).
Comparison of groups regarding number of patients with nausea (P  0.032),
omiting (P  0.028), and need for extra antiemetics (P  0.028) uncovered a
Table I. Nausea vomiting scale.
NVS Severity
0 No complaints
1 Mild nausea
2 Moderate nausea
3 Frequent vomiting (4 times)
4 Severe vomiting (continuous)
NVS  nausea vomiting scale.
Table II. Demographics characteristics.
Parameters
Group 1
(n  30)
Group 2
(n  30) P
Age, y 42.8 (9.9) 41.5 (7.8) 0.787
Weight, kg 72.8 (10.1) 70.5 (8.1) 0.895
Height, cm 165.3 (7.0) 166.4 (8.2) 0.916
Smoking, no. (%) 11 (36.7) 9 (30) 0.584
ASA (I/II), no. (%) 24 (80.0%)/6 (20.0) 25 (83.3%)/5 (16.7) 0.739
Gender (F/M), no. (%) 23 (76.7%)/7 (23.3) 25 (83.3%)/5 (16.7) 0.519
Duration of operation, min 105.5 (11.0) 110.5 (10.5) 0.625ASA  American Society of Anesthesiologists. Data are mean (SD) unless otherwise indicated.
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Current Therapeutic Researchsignificant difference at 0 to 4 hours but no significant differences at 4 to 12 and at
12 to 24 hours. There were significant differences between groups in the need for
additional antiemetics; 6 patients (20%) in group 1, and 14 patients (46.7%) in
group 2 required additional antiemetics (P  0.028) (Table IV).
The mean (SD) NVS score was 0.4 (0.2) in group 1 and 1.0 (0.2) in group 2 (P 
.017) (Table IV). The amount of additional antiemetics used was significantly
igher in group 2 than in group 1 (P  0.016). There were no differences between
roups for postoperative use of metamizole and nonsteroidal antiinflammatory drugs
P  0.05); however, a significant difference was found between group 1 and group
2 for additional antiemetic use (group 1, 6 [20%] and group 2, 14 [46.7%)]; P 
0.028).
No significant differences were found between groups for eye opening; time to
response to verbal stimulation; and orientation to place, time, and people (Table V).
Side effects are presented in Table VI. There were no differences between groups for
cough, laryngospasm, urinary retention, respiratory depression, or hiccup (Table VI).
Table III. Number of patients experiencing nausea or vomiting (n[%]).
Nausea/Vomiting
Group 1
(n  30)
Group 2
(n  30) P
Nausea
0–4 h 7 (23.3) 15 (50.0)* 0.032
4–12 h 6 (20.0) 7 (23.3) 0.754
12–24 h 0 (0) 0 (0) –
Vomiting
0–4 h 6 (20.0) 14 (46.7)* 0.028
4–12 h 2 (6.7) 4 (13.3) 0.671
12–24 h 0 (0) 0 (0) –
*P  0.05, compared with group 1.
Table IV. The number of patients subjected to NVS, additional antiemetics, and additional
antiemetics.
Group 1
(n  30)
Group 2
(n  30) P
Additional antiemetics patients, no. (%) 6 (20) 14 (46.7)* 0.028
NVS, mean (SD) 0.4 (0.2) 1.0 (0.2)* 0.017
Additional antiemetics, mean (SD), mg 2.0 (0.9) 6.3 (1.4)* 0.016
NVS  nausea vomiting scale.
*P  0.05 compared with group 1.
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In our study, patient demographics, type of surgical procedure, and anesthetic
administered were similar between groups. In addition, patients with a history of
motion sickness or previous postoperative emesis had been excluded from the study;
thus, the difference in incidence of PONV between groups was likely attributable to
variation in antiemetic drugs.
Our findings indicated that effectiveness of the combination of propofol plus
dexamethasone was significantly better than the combination of propofol plus meto-
clopramide.
Numerous agents have been used to treat PONV at varying dosages and time
intervals.2,20–25 Parameters such as nausea and vomiting scores for 4 hours in the
arly postoperative period or in the postoperative 24 hours, number of episodes and
everity of vomiting, number of antiemetics required, amount of antiemetics used,
ospitalization time, and problems caused by nausea and vomiting are studied to
valuate the effectiveness of these agents. In our study, the severity of nausea and
omiting was measured using the NVS for the postoperative 24 hours, and the
umber of patients with nausea, vomiting, or need for additional antiemetics was
ompared for postoperative hours 0 to 4, 4 to 12, and 12 to 24 hours; the results were
xpressed in percentages. We determined that the immediate postoperative bolus
Table V. Recovery periods. Data are mean (SD) unless otherwise indicated.
Parameters
Group 1
(n  30)
Group 2
(n  30) P
Opening eyes in response to verbal
commands (min)
2.1 (1.5) 1.8 (1.4) 0.486
Opening eyes spontaneously (min) 4.0 (3.1) 2.8 (1.8) 0.267
Orientation to place (min) 6.5 (3.9) 4.7 (3.2) 0.202
Orientation to time (min) 7.2 (4.3) 5.4 (3.4) 0.233
Orientation to people (min) 6.9 (3.9) 5.4 (3.4) 0.305
Data are mean (SD) unless otherwise indicated.
Table VI. Incidence of adverse reactions.
Adverse Reactions
Group 1
(n  30)
Group 2
(n  30) P
Cough 0 (0%) 1 (3.3%) 0.5
Laryngospasm 0 (0%) 1 (3.3%) 0.5
Urinary retention 0 (0%) 0 (0%) –
Respiratory depression 1 (3.3%) 1 (3.3%) –
Hiccup 0 (0%) 1 (3.3%) 0.5
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Current Therapeutic Researchdose of 0.5 mg/kg of propofol plus 8 mg dexamethasone was more effective than the
bolus dose of 0.5 mg/kg propofol plus 0.2 mg/kg metoclopramide for control of
PONV during the first 4 postoperative hours.
PONV develops as a complication after anesthesia, and if not prevented, recovery
and hospitalization time can be prolonged,2,25 leading to unpleasant hospital expe-
riences and increased health care costs.2 Prolonged vomiting may result in electrolyte
imbalance (hypocalcemia, hypochloremia, hyponatremic metabolic alkalosis) and
dehydration, Mallory-Weis tears, esophageal rupture, wound opening, and hematoma
formation under skin flaps after abdominal, vascular, eye, or plastic surgery.2,20,22
The effect of intraperitoneal insufflation of carbon dioxide (CO2) on residual
stretching and irritation of the peritoneum23 and duration of surgery15,26 are other
actors that affect PONV after LC. In our study, however, treatment groups were
imilar for patient demography, types of LC, anesthetics administered, and analgesics
sed postoperatively. Patients with a history of motion sickness, previous PONV, or
oth and women who were menstruating were excluded from the study because they
ave a remarkably high risk for PONV.15,26,27
Propofol used as an induction agent or continuously administered for maintenance
as found to cause less PONV compared with other induction agents and anesthesia
echniques.25,28 Despite a much lower incidence of PONV with the use of propofol,
n total IV anesthesia, high cost constitutes a negative aspect on its use for this
urpose.29–31 The antiemetic mechanism of propofol is not clearly known. This
haracteristic has been attributed to either its sedative effect or modulation of
ubcortical pathway21,32 and possibly due to its weak serotonin antagonist effect.21,33
The use of propofol for maintenance of anesthesia has a positive effect on PONV
eduction. Song et al7 have determined that low doses (0.5 mg/kg) of propofol infused
at the end of surgery in patients who have undergone LC under general anesthesia
reduce the incidence of PONV. Fujii and Nakayama34 have determined that low
oses of propofol plus dexamethasone at the end of surgery in patients who have
ndergone LC under general anesthesia reduce the incidence of PONV.
Fujii et al35 showed that a low dose (0.5 mg/kg) of propofol combined with 8 mg
of dexamethasone was more effective than propofol alone for the prevention of PONV
in adult Japanese patients having general anesthesia for extractions of third molars.
In our study, low-dose (0.5 mg/kg) propofol combined with dexamethasone (8 mg)
was administered; the prevention of PONV was comparable with that reported in
similar studies.18,34,35
Numazaki and Fujii33 have reported that the minimum dose of propofol for
effective prevention of PONV is 0.5 mg/kg given intravenously at the end of surgery;
when used at a dose of 0.25 mg/kg, its effect is no different from that of placebo.
These authors have also concluded that at doses of 0.5 mg/kg and 0.75 mg/kg,
propofol has similar effects; doses under 1 mg/kg yield less sedation, dysphoria, and
extrapyramidal signs, so 1 mg/kg is not recommended.33 Based on this information,
e used 0.5 mg/kg propofol (bolus dose).
Dexamethasone may offer additional benefits over traditional antiemetics in im-roving surgical outcomes. Compared with placebo, dexamethasone 8 mg IV given
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M. Arslan et al.90 minutes before LC has been reported to significantly reduce PONV.12 Although
8 mg IV is probably the most commonly used dose of dexamethasone for preventing
PONV in adults, the optimal dose has yet to be defined. One dose-finding study
reported 2.5 mg to be the minimum effective dose for preventing postoperative
vomiting in patients undergoing major gynecological surgery,36 whereas subsequent
studies reported 5 mg to be the minimum effective dose in patients undergoing
thyroidectomy.10 Dexamethasone is most effective in preventing PONV when it is
dministered immediately before induction of anesthesia rather than near the end of
nconsciousness.
The long-term administration of dexamethasone causes adverse effects, such as an
ncreased risk for infection, glucose intolerance, delayed wound healing, superficial
lceration of gastric mucosa, and adrenal suppression.37 In our study, however, these
adverse effects were not related to a single dose of dexamethasone. Adverse effects
observed in our study were not clinically important in any of the groups.
Metoclopramide is one option for conventional antiemetic treatment. Generally,
IV use of 10 mg or 0.2 mg/kg metoclopramide is recommended.23,38 Adverse effects
f metoclopramide include sedation, dizziness, and drowsiness. Extrapyramidal symp-
oms are not common but can occur and include feelings of weakness, anxiety,
gitation, and motor restlessness.39 Slow IV administration of metoclopramide and
administration of a preoperative anxiolytic sedative are important strategies for
reducing the risk of akathisia from the administration of IV metoclopramide.40
In earlier studies, the incidence of PONV associated with administration of nitrous
xide (N2O) was high. N2O is known to cause nausea and vomiting when adminis-
ered as the sole anesthetic agent. N2O can also cause PONV due to changes in
middle ear pressure and bowel distention due to diffusion into closed cavities.41 Gan
et al26 have recently reported consensus guidelines for managing PONV and con-
luded that the use of N2O during maintenance of anesthesia should be avoided. In
our study, therefore, we did not use this anesthetic gas.
It is known that positive pressure ventilation, a full stomach, and opioids and
anticholinergics used in premedication lead to increased PONV in anesthesia induc-
tion.2,42 In our study, no premedication was carried out. We tried to avoid strong
ositive pressure ventilation; before extubation, we performed gastric aspiration,
ecreasing the effect of such factors that increase nausea and vomiting in the
reoperative period.
To reduce the effect of patient- and anesthesia-specific factors, we homogenized
tudy groups for age, body weight, height, ASA group, sex, duration of operation, and
nesthesia. Such differences may account for differences observed in some studies.
Our study had potential limitations. First, the use of anticholinesterase and
tropine was not avoidable. Second, these data may not be applicable to different
urgical procedures or anesthetic techniques. Third, no prestudy power analysis was
erformed. Fourth, the original design included a placebo control group; however, the
nstitutional review board at our center decided that this would not be ethical because
he patients studied were at high risk for developing PONV.
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Current Therapeutic ResearchIn conclusion, subhypnotic bolus doses of propofol plus dexamethasone used at the
nd of LC were significantly more effective than propofol plus metoclopramide in
reventing PONV in this patient population. Additional studies are needed to
ompare the effectiveness of subhypnotic doses of propofol with other antiemetics.
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